Cargando…

Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy

BACKGROUND: The aim of the study was to evaluate predictive and prognostic significance of microtubule-associated protein Tau in epithelial ovarian cancer (EOC) patients treated with paclitaxel and platinum-based chemotherapy. METHODS: 74 patients with EOC (stage I-IV) who underwent cytoreductive su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smoter, Marta, Bodnar, Lubomir, Grala, Bartlomiej, Stec, Rafal, Zieniuk, Krystyna, Kozlowski, Wojciech, Szczylik, Cezary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654950/ https://www.ncbi.nlm.nih.gov/pubmed/23631819 http://dx.doi.org/10.1186/1756-9966-32-25

Ejemplares similares

The role of Tau protein in resistance to paclitaxel
por: Smoter, Marta, et al.
Publicado: (2011)

Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
por: Stec, Rafał, et al.
Publicado: (2009)

K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy
por: Stec, Rafał, et al.
Publicado: (2012)

Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system
por: Rokita, Marta, et al.
Publicado: (2013)

Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer
por: Bodnar, Lubomir, et al.
Publicado: (2014)

Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model
por: Chrom, Pawel, et al.
Publicado: (2018)

Prognostic Significance of Wnt-1, β-catenin and E-cadherin Expression in Advanced Colorectal Carcinoma
por: Stanczak, Aleksandra, et al.
Publicado: (2011)

Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma
por: Chrom, Pawel, et al.
Publicado: (2018)

Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies
por: Klemba, Aleksandra, et al.
Publicado: (2020)

Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients
por: Synowiec, Agnieszka, et al.
Publicado: (2016)

Malignant tumors in patients with end stage renal failure undergoing renal replacement therapy
por: Kade, Grzegorz, et al.
Publicado: (2012)

Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapy
por: Sigorski, Dawid, et al.
Publicado: (2020)

Colorectal cancer in the course of familial adenomatous polyposis syndrome (“de novo” pathogenic mutation of APC gene): case report, review of the literature and genetic commentary
por: Stec, Rafał, et al.
Publicado: (2010)

Axitinib in sequential therapy in metastatic renal cell carcinoma
por: Kuchar, Agata, et al.
Publicado: (2016)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2016)

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
por: Osman, Mohammed A., et al.
Publicado: (2016)

Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study
por: Wang, Liangliang, et al.
Publicado: (2023)

Integrated Analysis of Gene Expression Profiles Associated with Response of Platinum/Paclitaxel-Based Treatment in Epithelial Ovarian Cancer
por: Han, Yong, et al.
Publicado: (2012)

Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
por: Lam, Clarissa, et al.
Publicado: (2022)

Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature
por: Serkies, Krystyna, et al.
Publicado: (2011)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
por: Sandercock, J, et al.
Publicado: (2002)

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
por: Kavanagh, John J, et al.
Publicado: (2010)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer
por: Noronha, Vanita, et al.
Publicado: (2012)

Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum
por: Melichar, Bohuslav, et al.
Publicado: (2007)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer
por: Yu, Xiaotang, et al.
Publicado: (2020)

Accuracy of a remote quantitative image analysis in the whole slide images
por: Słodkowska, Janina, et al.
Publicado: (2011)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland
por: Sigorski, Dawid, et al.
Publicado: (2023)

Enhanced Efficacy of Neoadjuvant Chemotherapy with Nab-Paclitaxel and Platinum for Locally Advanced Cervical Cancer
por: Yu, Xiao-Li, et al.
Publicado: (2021)

Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
por: Groeneweg, Jolijn W., et al.
Publicado: (2014)

The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
por: Zhao, Hong, et al.
Publicado: (2020)

Blood bioactive sphingolipids in patients with advanced serous epithelial ovarian cancer – mass spectrometry analysis
por: Knapp, Paweł, et al.
Publicado: (2018)

Cross-validation of genes potentially associated with neoadjuvant chemotherapy and platinum-based chemoresistance in epithelial ovarian carcinoma
por: Zhang, Kai, et al.
Publicado: (2020)

The Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratios in Predicting Response to Platinum-based Chemotherapy for Epithelial Ovarian Cancer
por: Winarno, Gatot Nyarumenteng Adhipurnawan, et al.
Publicado: (2021)

Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer
por: Verdegaal, Els M E, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5v1ar4cihqi2dlt60sgf5ij5qe